Sino Biopharmaceutical gets FDA IND approval for TQB6426 GPC3 ADC
Sino Biopharmaceutical Limited says the FDA has granted IND approval for TQB6426, a GPC3 ADC, for advanced malignant tumors.
Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
1 result loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Sino Biopharmaceutical Limited says the FDA has granted IND approval for TQB6426, a GPC3 ADC, for advanced malignant tumors.